10-K: Instil Bio Reports FY2024 Results, Focuses on Bispecific Antibody Development

Instil Bio shifts focus to bispecific antibody AXN-2510/IMM2510, reports \$74.1 million net loss for FY2024, and anticipates funding operations beyond 2026.

Summary

• Instil Bio, a clinical-stage biopharmaceutical company, is now prioritizing the development of AXN-2510/IMM2510, a bispecific antibody, and seeking additional therapeutic assets.
• The company has discontinued active pursuit of cell therapies, including its CoStAR-TIL cell therapy.
• In August 2024, Instil Bio in-licensed AXN-2510/IMM2510 and AXN-27M/IMM27M from ImmuneOnco Biopharmaceuticals, gaining exclusive rights outside of Greater China.
• ImmuneOnco is currently conducting Phase 1 clinical trials in China, with over 100 patients enrolled in an AXN-2510/IMM2510 monotherapy trial as of January 13, 2025.
• Instil Bio reported a net loss of \$74.1 million for the year ended December 31, 2024, compared to a net loss of \$156.1 million for the year ended December 31, 2023.
• As of December 31, 2024, the company's accumulated deficit was \$655.1 million.
• The company believes its existing cash, cash equivalents, and marketable securities of \$115.1 million will be sufficient to fund operating expenses and capital requirements beyond 2026.
• Instil Bio owns a manufacturing facility in Tarzana, California, which is currently leased to AstraZeneca and is being evaluated for potential sale.
• As of December 31, 2024, the company had 14 full-time employees.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is focusing on a promising bispecific antibody candidate and has sufficient cash runway, it also reported a significant net loss and has an accumulated deficit. The shift in strategy and potential sale of the Tarzana facility add uncertainty.

Positives

• The company is focusing on a promising bispecific antibody candidate, AXN-2510/IMM2510.
• The company has secured exclusive rights to AXN-2510/IMM2510 outside of Greater China.
• The company's net loss decreased significantly from FY2023 to FY2024.
• The company has sufficient cash runway to fund operations beyond 2026.

Negatives

• The company reported a significant net loss of \$74.1 million for FY2024.
• The company has an accumulated deficit of \$655.1 million as of December 31, 2024.
• The company has discontinued development of cell therapies, including its CoStAR-TIL cell therapy.

Risks

• The company is dependent on the success of AXN-2510/IMM2510, which is in early-stage clinical development.
• The company relies on ImmuneOnco for manufacturing clinical supplies of AXN-2510/IMM2510.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company may be unable to obtain and maintain sufficient patent protection for its product candidates.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and data security.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements beyond 2026. The company is evaluating opportunities for a potential sale of its Tarzana facility, which is leased to AstraZeneca, and AstraZeneca has the right of first offer to purchase the Tarzana facility. If the company is successful in selling the Tarzana facility, such a transaction could extend the company's expected cash runway.

Industry Context

The biopharmaceutical industry is characterized by rapid technological advancements and intense competition. Instil Bio faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic research institutions and governmental agencies.

Comparison to Industry Standards

• The document mentions several competitors developing bispecific PD-1xVEGF or PD-L1xVEGF antibodies, including BioNTech SE, Crescent Biopharma, Merck & Co., Inc., Ottimo Pharma and Summit Therapeutics Inc.
• The document also mentions competition from companies utilizing other therapeutic approaches in the oncology market, such as surgery, radiation, chemotherapy, hormone therapy, biologic therapy, immunotherapy, cell-based therapy and targeted therapy.
• The document does not provide specific details on the financial performance of these competitors or benchmarks for comparison.

Stakeholder Impact

• Shareholders: The shift in strategy and potential sale of the Tarzana facility may impact shareholder value.
• Employees: Restructuring plans have resulted in workforce reductions.
• Customers: The focus on AXN-2510/IMM2510 may lead to new treatment options for patients with solid tumor cancers.

Next Steps

• Advance development of AXN-2510/IMM2510, including initiating clinical development outside of China.
• Pursue additional promising therapeutic in-licensing or acquisition opportunities.
• Evaluate options to potentially sell the Tarzana, California facility.

Key Dates